Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic oral bacteria collectively refer to numerous bacterial species capable of causing oral diseases. These include gram-negative anaerobes (such as Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola), as well as facultative anaerobes like Streptococcus mutans and Aggregatibacter actinomycetemcomitans. These bacteria reside in the oral cavity, frequently form part of polymicrobial biofilms (dental plaque), and contribute to dental caries, periodontal disease, and other oral infections. They exhibit diverse pathogenic mechanisms, including biofilm formation, acid production, immune modulation, and the secretion of proteases and toxins. Due to their diverse nature, "pathogenic oral bacteria" are not a single molecular target but rather a descriptor of a functional group relevant in infectious disease and oral health[1][3][4][5][6].
Bacterial cell wall synthesis inhibition (beta-lactams); Protein synthesis inhibition (macrolides, tetracyclines, clindamycin); DNA synthesis inhibition (fluoroquinolones, metronidazole); Membrane disruption (chlorhexidine)
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic oral bacterium (null).